Evaluation of In Vitro Tests for Identifying Eye Injury Hazard Potential of Chemicals and Products: Request for Nominations for an Independent Expert Panel and Submission of Relevant Data, 41406-41408 [2012-17118]
Download as PDF
41406
Federal Register / Vol. 77, No. 135 / Friday, July 13, 2012 / Notices
institutions to report known or
suspected violations of law and
suspicious transactions. To fulfill these
requirements, supervised banking
organizations file SARs. Law
enforcement agencies use the
information submitted on the reporting
form to initiate investigations and the
Federal Reserve uses the information in
the examination and oversight of
supervised institutions.
Current actions: On April 23, 2012,
the Federal Reserve published a notice
in the Federal Register (77 FR 24205)
requesting public comment for 60 days
on the extension, without revision, of
the interagency Suspicious Activities
Report by Depository Institutions. The
comment period for this notice expired
on June 22, 2012. The Federal Reserve
did not receive any comments.
Board of Governors of the Federal Reserve
System, July 10, 2012.
Jennifer J. Johnson,
Secretary of the Board.
[FR Doc. 2012–17183 Filed 7–12–12; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Request for Public Comment on a
Nomination to the Office of Health
Assessment and Translation
Division of the National
Toxicology Program (DNTP), National
Institute of Environmental Health
Sciences (NIEHS), National Institutes of
Health (NIH).
ACTION: Request for public comment.
AGENCY:
The NTP requests comments
on Air Pollution and Children’s Health,
which was nominated for a possible
evaluation by the Office of Health
Assessment and Translation (OHAT).
This nomination focuses on substances,
mixtures, and exposure circumstances
(collectively referred to as ‘‘substances’’)
related to traffic/near road air pollution
and their association with emerging
children’s health outcomes.
DATES: The deadline for submission of
public comments on the nominated
substances is August 24, 2012;
comments submitted after this date will
be considered as time permits.
ADDRESSES: Comments should be sent to
Dr. Kembra Howdeshell, Office of
Health Assessment and Translation,
DNTP, NIEHS, P.O. Box 12233, MD K2–
04, Research Triangle Park, NC 27709;
telephone (919) 316–4708; FAX: (919)
316–4511; howdeshellkl@niehs.nih.gov.
Courier address: NIEHS, Room 2161,
530 Davis Drive, Morrisville, NC 27560.
srobinson on DSK4SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
17:08 Jul 12, 2012
Jkt 226001
Comments can also be submitted online
at the OHAT Web site (https://
ntp.niehs.nih.gov/go/evals).
FOR FURTHER INFORMATION CONTACT: Dr.
Kembra Howdeshell (telephone: (919)
316–4708 or email
howdeshellkl@niehs.nih.gov).
SUPPLEMENTARY INFORMATION:
Request for Public Comment on
Nomination to OHAT
The NTP requests public comment on
the nomination of Air Pollution and
Children’s Health for possible
evaluation by OHAT. Specifically, the
NTP requests information on the
following topics: (1) Current exposures
and health outcomes considered in this
nomination (see list below and the draft
literature search strategy provided on
the OHAT Web site (https://
ntp.niehs.gov/go/evals), (2) published,
ongoing, or planned studies related to
traffic/near road air pollution and
children’s health, (3) scientific issues
important for assessing emerging health
outcomes in children associated with
traffic/near road air pollution, and (4)
names of scientists with expertise or
knowledge about traffic/near road air
pollution and children’s health. Please
include any available bibliographic
citations for the information. The NTP
will use this information for refining the
draft literature search strategy for the
nomination prior to a potential formal
evaluation by OHAT.
The exposures associated with the
nomination include air pollution and
the following components: benzene,
carbon monoxide, diesel, nitrogen
oxides, ozone, particulate matter (PM10,
PM2.5, coarse PM, and ultrafine PM),
polyaromatic hydrocarbons, and sulfur
oxides. The emerging children’s health
outcomes associated with the
nomination include: Incidence and
exacerbation of asthma, incidence of
allergic disease, adverse birth outcomes
(i.e., premature birth, small for
gestational age birth weight, and
congenital anomalies), respiratory
infections in early life, pediatric cancer,
development of the nervous system,
modifying risk of adult onset diseases
(i.e., fetal basis of adult cardiovascular,
metabolic or chronic obstructive
pulmonary disease), and compromised
lung function, development, and
growth. Several important air
contaminants, including tobacco smoke,
mercury, lead, arsenic, indoor
aeroallergens, and indoor volatile
organic compounds, are not included
because they have been addressed in
other comprehensive reviews.
Persons submitting public comments
are asked to include their name, contact
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
information, affiliation, and sponsoring
organization (if any) and to send them
to Dr. Howdeshell (see ADDRESSES
above). All information received will be
posted on the OHAT Web site and the
submitter identified by name, affiliation,
and sponsoring organization, if
applicable. The deadline for submission
of public comment is August 24, 2012.
Comments and information received
after that date will be added to the
public record and used by the NTP, as
time permits, in refining the literature
search strategy and scope of this
nomination for potential evaluation by
OHAT.
Background Information on OHAT
The NTP and the National Institute of
Environmental Health Sciences
established the Office of Health
Assessment and Translation (OHAT) to
serve as an environmental health
resource to the public and to regulatory
and health agencies. This office
conducts evaluations to assess the
evidence that environmental chemicals,
physical substances, or mixtures
(collectively referred to as ‘‘substances’’)
cause adverse health effects and
provides opinions on whether these
substances may be of concern given
what is known about current human
exposure levels. OHAT evaluations are
published as NTP Monographs. OHAT
also organizes state-of-the-science
workshops to address issues of
importance in environmental health
sciences. Information about the OHAT
is available on the OHAT Web site
(https://ntp.niehs.gov/go/ohat) or by
contacting Dr. Howdeshell (see
ADDRESSES).
Dated: July 5, 2012.
John R. Bucher,
Associate Director, National Toxicology
Program.
[FR Doc. 2012–17114 Filed 7–12–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Evaluation of In Vitro Tests for
Identifying Eye Injury Hazard Potential
of Chemicals and Products: Request
for Nominations for an Independent
Expert Panel and Submission of
Relevant Data
Division of the National
Toxicology Program (DNTP), National
Institute of Environmental Health
Sciences (NIEHS), National Institutes of
Health (NIH).
ACTION: Request for Data; Request for
Nomination of Scientific Experts.
AGENCY:
E:\FR\FM\13JYN1.SGM
13JYN1
Federal Register / Vol. 77, No. 135 / Friday, July 13, 2012 / Notices
The NTP Interagency Center
for the Evaluation of Alternative
Toxicological Methods (NICEATM), in
collaboration with the Interagency
Coordinating Committee on the
Validation of Alternative Methods
(ICCVAM), is planning to convene an
independent scientific peer review
panel (Panel) to assess the validation
status of in vitro tests and integrated
non-animal testing strategies proposed
for identifying eye injury hazard
potential of chemicals and products. On
behalf of ICCVAM, NICEATM requests
nominations of scientific experts who
can be considered for the Panel and
submission of data from substances
tested in in vitro tests for identifying eye
injury hazard potential. Of particular
interest are data generated in the shorttime exposure (STE) (Takahashi et al.,
2008) and isolated rabbit eye (IRE)
(ICCVAM, 2006, 2010a) tests and data
from approaches using two or more in
vitro tests. However, NICEATM requests
data from other tests including, but not
limited to, the bovine corneal opacity
and permeability (BCOP), isolated
chicken eye (ICE), hen’s egg test—
chorioallantoic membrane (HET–CAM),
Cytosensor microphysiometer (CM),
fluorescein leakage (FL), SkinEthicTM
human corneal epithelium, and
EpiOcularTM tests. If available,
corresponding in vivo data for these
substances are also requested, including
data from any ethical human or animal
studies or accidental human exposures.
DATES: Nominations and test method
data for the STE and IRE tests should be
submitted by August 27, 2012. Data
submitted after this date will be
considered in the evaluation where
feasible.
FOR FURTHER INFORMATION CONTACT: Dr.
William S. Stokes, Director, NICEATM,
NIEHS, P.O. Box 12233, Mail Stop: K2–
16, Research Triangle Park, NC 27709,
(telephone) 919–541–2384, (fax) 919–
541–0947, (email)
niceatm@niehs.nih.gov. Courier address:
NICEATM, NIEHS, Room 2034, 530
Davis Drive, Morrisville, NC 27560.
SUPPLEMENTARY INFORMATION:
srobinson on DSK4SPTVN1PROD with NOTICES
SUMMARY:
Background
The development of in vitro
alternatives to animals for eye safety
assessments is an ICCVAM priority
(ICCVAM, 2008). See https://
iccvam.niehs.nih.gov/methods/ocutox/
ocutox.htm for more information on
ICCVAM evaluations of ocular toxicity
test methods. An efficient non-animal
evaluation of substances for their eye
hazard potential is expected to require
a number of adequately validated in
vitro tests that can be considered for use
VerDate Mar<15>2010
17:08 Jul 12, 2012
Jkt 226001
in integrated testing and decision
strategies. In vivo reference data and in
vitro test data for available methods is
sought to support the validity of
individual methods and to construct
integrated testing and decision strategies
using multiple methods.
In 2006, ICCVAM evaluated the
validation status of the in vitro tests
BCOP, ICE, HET–CAM, and IRE for their
usefulness and limitation for identifying
ocular corrosives and severe irritants
(ICCVAM, 2006). ICCVAM concluded
that BCOP and ICE had sufficient
relevance and reliability to support their
use for identifying certain types of
substances as ocular corrosives and
severe irritants for regulatory hazard
classification. Subsequently, BCOP and
ICE were adopted as Organisation for
Economic Co-operation and
Development (OECD) Test Guidelines
437 and 438, respectively (OECD, 2009a,
2009b). The IRE and HET–CAM tests
lacked sufficient data and/or had
insufficient relevance and reliability to
support their use for regulatory hazard
classification.
In 2009, ICCVAM evaluated the
validation status of these four in vitro
tests for identifying eye injury hazard
potential, along with the CM test, to
assess their usefulness for identifying
nonsevere eye irritants and substances
not classified as irritants (ICCVAM,
2010a). ICCVAM concluded that the CM
test could be used as a screening test to
identify some types of substances that
may cause permanent or severe eye
injuries. ICCVAM also recommended
that the CM test could be used to
determine if some types of substances
will not cause sufficient injury to
require hazard classification for eye
irritation. The predictivity of the
remaining four in vitro tests was
considered insufficient to support their
use for identifying substances that may
cause reversible and nonsevere eye
injuries.
ICCVAM also evaluated the validation
status of the antimicrobial cleaning
products (AMCP) testing strategy, which
included the BCOP, CM, and
EpiOcularTM tests. ICCVAM concluded
that the data were insufficient to
adequately demonstrate that the AMCP
testing strategy can identify all four U.S.
Environmental Protection Agency (EPA)
eye hazard categories (ICCVAM, 2010b).
An EPA-implemented voluntary pilot
program is ongoing to evaluate the use
of the AMCP testing strategy for eye
irritation labeling for certain
antimicrobial products (https://
www.epa.gov/oppad001/eyeirritation.pdf).
The IRE test is an organotypic test
method that evaluates the eye injury
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
41407
potential of a test substance by
measuring corneal opacity, corneal
swelling, epithelial integrity, and
fluorescein staining. During the
previous evaluations of the IRE test,
ICCVAM recommended further
standardization of the test protocol and
additional studies using all four
endpoints to expand the IRE test
validation database (ICCVAM, 2006,
2010a).
The STE test measures the viability of
rabbit corneal epithelial cells following
test substance exposure (Takahashi et
al., 2008). NICEATM is requesting
additional data that can be considered
in assessing the validity of the STE and
the IRE. Other test methods and
integrated testing and decision strategies
will also be considered for review if
there are sufficient new data available.
For test methods and strategies for
which there are sufficient data, ICCVAM
will develop draft recommendations on
test method usefulness and limitations,
standardized test method protocols,
future studies that may expand the
usefulness of the test method, and test
method performance standards. These
draft recommendations and supporting
data will be provided to the Panel and
made available to the public. The Panel
will meet in public session to review the
validation status of the proposed
methods and comment on the extent to
which the data support the draft
ICCVAM test method recommendations.
Meeting information, including dates,
locations, and public availability of the
meeting documents will be announced
in a future Federal Register notice and
will also be posted on the NICEATM–
ICCVAM Web site (https://
iccvam.niehs.nih.gov).
Request for Nominations of Scientific
Experts
NICEATM requests nominations of
scientists with relevant knowledge and
expertise to serve on the Panel. Areas of
relevant expertise include, but are not
limited to biostatistics; human and
veterinary ophthalmology, with an
emphasis on evaluation and treatment
of chemical injuries; in vivo eye safety
testing; in vitro eye safety testing; and
test method validation. Each
nomination should include the
nominee’s name, affiliation, contact
information (i.e., mailing address, email
address, telephone and fax numbers),
curriculum vitae, and a brief summary
of relevant experience and
qualifications.
Request for Data
NICEATM invites the submission of
data from substances tested in any in
vitro test and integrated non-animal
E:\FR\FM\13JYN1.SGM
13JYN1
41408
Federal Register / Vol. 77, No. 135 / Friday, July 13, 2012 / Notices
srobinson on DSK4SPTVN1PROD with NOTICES
testing strategies proposed for
identifying eye injury hazard potential
of chemicals and products. If available,
in vivo reference data for substances
tested in these data sets are also
requested. Although data can be
accepted at any time, please submit data
by August 27, 2012 to ensure
consideration during the ICCVAM
evaluation process. Relevant data
received after this date will be
considered where feasible. All
information submitted in response to
this notice will be made publicly
available and may be incorporated into
future NICEATM and ICCVAM reports
and publications, as appropriate.
When submitting data, please
reference this Federal Register notice
and provide appropriate contact
information (name, affiliation, mailing
address, phone, fax, email, and
sponsoring organization, as applicable).
NICEATM prefers that data be
submitted as copies of pages from study
notebooks and/or study reports, if
available. Laboratory data and analyses
available in electronic format may also
be submitted. Each submission for a
substance should preferably include the
following information, as appropriate:
common and trade name, Chemical
Abstracts Service Registry Number
(CASRN), commercial source, in vitro
test protocol used, rabbit eye test
protocol used, individual animal or in
vitro responses at each observation time
(i.e., raw data), extent to which the data
were collected in accordance with
national or international Good
Laboratory Practice guidelines, date and
testing organization, and physical and
chemical properties (e.g., molecular
weight, pH, water solubility, etc.)
Background Information on ICCVAM
and NICEATM
ICCVAM is an interagency committee
composed of representatives from 15
Federal regulatory and research agencies
that require, use, generate, or
disseminate toxicological and safety
testing information. ICCVAM conducts
technical evaluations of new, revised,
and alternative safety testing methods
and integrated testing strategies with
regulatory applicability and promotes
the scientific validation and regulatory
acceptance of testing methods that more
accurately assess the safety and hazards
of chemicals and products and that
reduce, refine (enhance animal wellbeing and lessen or avoid pain and
distress), or replace animal use. The
ICCVAM Authorization Act of 2000 (42
U.S.C. 285l–3) established ICCVAM as a
permanent interagency committee of the
NIEHS under NICEATM. NICEATM
administers ICCVAM, provides
VerDate Mar<15>2010
17:08 Jul 12, 2012
Jkt 226001
scientific and operational support for
ICCVAM-related activities, and
conducts independent validation
studies to assess the usefulness and
limitations of new, revised, and
alternative test methods and strategies.
NICEATM and ICCVAM welcome the
public nomination of new, revised, and
alternative test methods and strategies
for validation studies and technical
evaluations. Additional information
about NICEATM and ICCVAM can be
found on the NICEATM–ICCVAM Web
site (https://iccvam.niehs.nih.gov).
References
ICCVAM. 2006. ICCVAM Test Method
Evaluation Report: In Vitro Ocular
Toxicity Test Methods for Identifying
Severe Irritants and Corrosives. NIH
Publication No. 07–4517. Research
Triangle Park, NC: NIEHS. Available:
https://iccvam.niehs.nih.gov/methods/
ocutox/ivocutox/ocu_tmer.htm.
ICCVAM. 2008. The NICEATM–
ICCVAM Five-Year Plan (2008–2012): A
Plan to Advance Alternative Test
Methods of High Scientific Quality to
Protect and Advance the Health of
People, Animals, and the Environment.
NIH Publication No. 08–6410. Research
Triangle Park, NC: NIEHS. Available:
https://iccvam.niehs.nih.gov/docs/
5yearplan.htm.
ICCVAM. 2010a. ICCVAM Test
Method Evaluation Report: Current
Validation Status of In Vitro Test
Methods Proposed for Identifying Eye
Injury Hazard Potential of Chemicals
and Products. NIH Publication No. 10–
7553. Research Triangle Park, NC:
NIEHS. Available: https://
iccvam.niehs.nih.gov/methods/ocutox/
MildMod-TMER.htm.
ICCVAM. 2010b. ICCVAM Test
Method Evaluation Report: Current
Validation Status of a Proposed In Vitro
Testing Strategy for U.S. Environmental
Protection Agency Ocular Hazard
Classification and Labeling of
Antimicrobial Cleaning Products. NIH
Publication No. 10–7513. Research
Triangle Park, NC: NIEHS. Available:
https://iccvam.niehs.nih.gov/methods/
ocutox/antimicro/TMER.htm.
OECD. 2009a. Test Guideline 437.
Bovine Corneal Opacity and
Permeability Test Method for
Identifying Ocular Corrosives and
Severe Irritants [adopted 7 September
2009]. In: OECD Guidelines for the
Testing of Chemicals, Section 4: Health
Effects. Paris:OECD Publishing.
Available: https://www.oecd-ilibrary.org/
environment/test-no-437-bovinecorneal-opacity-and-permeability-testmethod-for-identifying-ocularcorrosives-and-severeirritants_9789264076303-en.
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
OECD. 2009b. Test No. 438. Isolated
Chicken Eye Test Method for Identifying
Ocular Corrosives and Severe Irritants
[adopted 7 September 2009]. In: OECD
Guidelines for Testing of Chemicals.
Paris:OECD Publishing. Available:
https://www.oecd-ilibrary.org/
environment/test-no-438-isolatedchicken-eye-test-method-for-identifyingocular-corrosives-and-severeirritants_9789264076310-en.
Takahashi Y, Koike M, Honda H, Ito Y,
Sakaguchi H, Suzuki H, Nishiyama
N. 2008. Development of the short
time exposure (STE) test: an in vitro
eye irritation test using SIRC cells.
Toxicol In Vitro 22:760–770.
Dated: July 5, 2012.
John R. Bucher,
Associate Director, National Toxicology
Program.
[FR Doc. 2012–17118 Filed 7–12–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0114]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Request for
Samples and Protocols
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by August 13,
2012.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, Fax: 202–
395–7285, or emailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0206. Also
include the FDA docket number found
in brackets in the heading of this
document.
SUMMARY:
Ila
S. Mizrachi, Food and Drug
Administration, 1350 Piccard Dr., PI50–
FOR FURTHER INFORMATION CONTACT:
E:\FR\FM\13JYN1.SGM
13JYN1
Agencies
[Federal Register Volume 77, Number 135 (Friday, July 13, 2012)]
[Notices]
[Pages 41406-41408]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-17118]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Evaluation of In Vitro Tests for Identifying Eye Injury Hazard
Potential of Chemicals and Products: Request for Nominations for an
Independent Expert Panel and Submission of Relevant Data
AGENCY: Division of the National Toxicology Program (DNTP), National
Institute of Environmental Health Sciences (NIEHS), National Institutes
of Health (NIH).
ACTION: Request for Data; Request for Nomination of Scientific Experts.
-----------------------------------------------------------------------
[[Page 41407]]
SUMMARY: The NTP Interagency Center for the Evaluation of Alternative
Toxicological Methods (NICEATM), in collaboration with the Interagency
Coordinating Committee on the Validation of Alternative Methods
(ICCVAM), is planning to convene an independent scientific peer review
panel (Panel) to assess the validation status of in vitro tests and
integrated non-animal testing strategies proposed for identifying eye
injury hazard potential of chemicals and products. On behalf of ICCVAM,
NICEATM requests nominations of scientific experts who can be
considered for the Panel and submission of data from substances tested
in in vitro tests for identifying eye injury hazard potential. Of
particular interest are data generated in the short-time exposure (STE)
(Takahashi et al., 2008) and isolated rabbit eye (IRE) (ICCVAM, 2006,
2010a) tests and data from approaches using two or more in vitro tests.
However, NICEATM requests data from other tests including, but not
limited to, the bovine corneal opacity and permeability (BCOP),
isolated chicken eye (ICE), hen's egg test--chorioallantoic membrane
(HET-CAM), Cytosensor microphysiometer (CM), fluorescein leakage (FL),
SkinEthicTM human corneal epithelium, and
EpiOcularTM tests. If available, corresponding in vivo data
for these substances are also requested, including data from any
ethical human or animal studies or accidental human exposures.
DATES: Nominations and test method data for the STE and IRE tests
should be submitted by August 27, 2012. Data submitted after this date
will be considered in the evaluation where feasible.
FOR FURTHER INFORMATION CONTACT: Dr. William S. Stokes, Director,
NICEATM, NIEHS, P.O. Box 12233, Mail Stop: K2-16, Research Triangle
Park, NC 27709, (telephone) 919-541-2384, (fax) 919-541-0947, (email)
niceatm@niehs.nih.gov. Courier address: NICEATM, NIEHS, Room 2034, 530
Davis Drive, Morrisville, NC 27560.
SUPPLEMENTARY INFORMATION:
Background
The development of in vitro alternatives to animals for eye safety
assessments is an ICCVAM priority (ICCVAM, 2008). See https://iccvam.niehs.nih.gov/methods/ocutox/ocutox.htm for more information on
ICCVAM evaluations of ocular toxicity test methods. An efficient non-
animal evaluation of substances for their eye hazard potential is
expected to require a number of adequately validated in vitro tests
that can be considered for use in integrated testing and decision
strategies. In vivo reference data and in vitro test data for available
methods is sought to support the validity of individual methods and to
construct integrated testing and decision strategies using multiple
methods.
In 2006, ICCVAM evaluated the validation status of the in vitro
tests BCOP, ICE, HET-CAM, and IRE for their usefulness and limitation
for identifying ocular corrosives and severe irritants (ICCVAM, 2006).
ICCVAM concluded that BCOP and ICE had sufficient relevance and
reliability to support their use for identifying certain types of
substances as ocular corrosives and severe irritants for regulatory
hazard classification. Subsequently, BCOP and ICE were adopted as
Organisation for Economic Co-operation and Development (OECD) Test
Guidelines 437 and 438, respectively (OECD, 2009a, 2009b). The IRE and
HET-CAM tests lacked sufficient data and/or had insufficient relevance
and reliability to support their use for regulatory hazard
classification.
In 2009, ICCVAM evaluated the validation status of these four in
vitro tests for identifying eye injury hazard potential, along with the
CM test, to assess their usefulness for identifying nonsevere eye
irritants and substances not classified as irritants (ICCVAM, 2010a).
ICCVAM concluded that the CM test could be used as a screening test to
identify some types of substances that may cause permanent or severe
eye injuries. ICCVAM also recommended that the CM test could be used to
determine if some types of substances will not cause sufficient injury
to require hazard classification for eye irritation. The predictivity
of the remaining four in vitro tests was considered insufficient to
support their use for identifying substances that may cause reversible
and nonsevere eye injuries.
ICCVAM also evaluated the validation status of the antimicrobial
cleaning products (AMCP) testing strategy, which included the BCOP, CM,
and EpiOcularTM tests. ICCVAM concluded that the data were
insufficient to adequately demonstrate that the AMCP testing strategy
can identify all four U.S. Environmental Protection Agency (EPA) eye
hazard categories (ICCVAM, 2010b). An EPA-implemented voluntary pilot
program is ongoing to evaluate the use of the AMCP testing strategy for
eye irritation labeling for certain antimicrobial products (https://www.epa.gov/oppad001/eye-irritation.pdf).
The IRE test is an organotypic test method that evaluates the eye
injury potential of a test substance by measuring corneal opacity,
corneal swelling, epithelial integrity, and fluorescein staining.
During the previous evaluations of the IRE test, ICCVAM recommended
further standardization of the test protocol and additional studies
using all four endpoints to expand the IRE test validation database
(ICCVAM, 2006, 2010a).
The STE test measures the viability of rabbit corneal epithelial
cells following test substance exposure (Takahashi et al., 2008).
NICEATM is requesting additional data that can be considered in
assessing the validity of the STE and the IRE. Other test methods and
integrated testing and decision strategies will also be considered for
review if there are sufficient new data available.
For test methods and strategies for which there are sufficient
data, ICCVAM will develop draft recommendations on test method
usefulness and limitations, standardized test method protocols, future
studies that may expand the usefulness of the test method, and test
method performance standards. These draft recommendations and
supporting data will be provided to the Panel and made available to the
public. The Panel will meet in public session to review the validation
status of the proposed methods and comment on the extent to which the
data support the draft ICCVAM test method recommendations. Meeting
information, including dates, locations, and public availability of the
meeting documents will be announced in a future Federal Register notice
and will also be posted on the NICEATM-ICCVAM Web site (https://iccvam.niehs.nih.gov).
Request for Nominations of Scientific Experts
NICEATM requests nominations of scientists with relevant knowledge
and expertise to serve on the Panel. Areas of relevant expertise
include, but are not limited to biostatistics; human and veterinary
ophthalmology, with an emphasis on evaluation and treatment of chemical
injuries; in vivo eye safety testing; in vitro eye safety testing; and
test method validation. Each nomination should include the nominee's
name, affiliation, contact information (i.e., mailing address, email
address, telephone and fax numbers), curriculum vitae, and a brief
summary of relevant experience and qualifications.
Request for Data
NICEATM invites the submission of data from substances tested in
any in vitro test and integrated non-animal
[[Page 41408]]
testing strategies proposed for identifying eye injury hazard potential
of chemicals and products. If available, in vivo reference data for
substances tested in these data sets are also requested. Although data
can be accepted at any time, please submit data by August 27, 2012 to
ensure consideration during the ICCVAM evaluation process. Relevant
data received after this date will be considered where feasible. All
information submitted in response to this notice will be made publicly
available and may be incorporated into future NICEATM and ICCVAM
reports and publications, as appropriate.
When submitting data, please reference this Federal Register notice
and provide appropriate contact information (name, affiliation, mailing
address, phone, fax, email, and sponsoring organization, as
applicable). NICEATM prefers that data be submitted as copies of pages
from study notebooks and/or study reports, if available. Laboratory
data and analyses available in electronic format may also be submitted.
Each submission for a substance should preferably include the following
information, as appropriate: common and trade name, Chemical Abstracts
Service Registry Number (CASRN), commercial source, in vitro test
protocol used, rabbit eye test protocol used, individual animal or in
vitro responses at each observation time (i.e., raw data), extent to
which the data were collected in accordance with national or
international Good Laboratory Practice guidelines, date and testing
organization, and physical and chemical properties (e.g., molecular
weight, pH, water solubility, etc.)
Background Information on ICCVAM and NICEATM
ICCVAM is an interagency committee composed of representatives from
15 Federal regulatory and research agencies that require, use,
generate, or disseminate toxicological and safety testing information.
ICCVAM conducts technical evaluations of new, revised, and alternative
safety testing methods and integrated testing strategies with
regulatory applicability and promotes the scientific validation and
regulatory acceptance of testing methods that more accurately assess
the safety and hazards of chemicals and products and that reduce,
refine (enhance animal well-being and lessen or avoid pain and
distress), or replace animal use. The ICCVAM Authorization Act of 2000
(42 U.S.C. 285l-3) established ICCVAM as a permanent interagency
committee of the NIEHS under NICEATM. NICEATM administers ICCVAM,
provides scientific and operational support for ICCVAM-related
activities, and conducts independent validation studies to assess the
usefulness and limitations of new, revised, and alternative test
methods and strategies. NICEATM and ICCVAM welcome the public
nomination of new, revised, and alternative test methods and strategies
for validation studies and technical evaluations. Additional
information about NICEATM and ICCVAM can be found on the NICEATM-ICCVAM
Web site (https://iccvam.niehs.nih.gov).
References
ICCVAM. 2006. ICCVAM Test Method Evaluation Report: In Vitro Ocular
Toxicity Test Methods for Identifying Severe Irritants and Corrosives.
NIH Publication No. 07-4517. Research Triangle Park, NC: NIEHS.
Available: https://iccvam.niehs.nih.gov/methods/ocutox/ivocutox/ocu_tmer.htm.
ICCVAM. 2008. The NICEATM-ICCVAM Five-Year Plan (2008-2012): A Plan
to Advance Alternative Test Methods of High Scientific Quality to
Protect and Advance the Health of People, Animals, and the Environment.
NIH Publication No. 08-6410. Research Triangle Park, NC: NIEHS.
Available: https://iccvam.niehs.nih.gov/docs/5yearplan.htm.
ICCVAM. 2010a. ICCVAM Test Method Evaluation Report: Current
Validation Status of In Vitro Test Methods Proposed for Identifying Eye
Injury Hazard Potential of Chemicals and Products. NIH Publication No.
10-7553. Research Triangle Park, NC: NIEHS. Available: https://iccvam.niehs.nih.gov/methods/ocutox/MildMod-TMER.htm.
ICCVAM. 2010b. ICCVAM Test Method Evaluation Report: Current
Validation Status of a Proposed In Vitro Testing Strategy for U.S.
Environmental Protection Agency Ocular Hazard Classification and
Labeling of Antimicrobial Cleaning Products. NIH Publication No. 10-
7513. Research Triangle Park, NC: NIEHS. Available: https://iccvam.niehs.nih.gov/methods/ocutox/antimicro/TMER.htm.
OECD. 2009a. Test Guideline 437. Bovine Corneal Opacity and
Permeability Test Method for Identifying Ocular Corrosives and Severe
Irritants [adopted 7 September 2009]. In: OECD Guidelines for the
Testing of Chemicals, Section 4: Health Effects. Paris:OECD Publishing.
Available: https://www.oecd-ilibrary.org/environment/test-no-437-bovine-corneal-opacity-and-permeability-test-method-for-identifying-ocular-corrosives-and-severe-irritants_9789264076303-en.
OECD. 2009b. Test No. 438. Isolated Chicken Eye Test Method for
Identifying Ocular Corrosives and Severe Irritants [adopted 7 September
2009]. In: OECD Guidelines for Testing of Chemicals. Paris:OECD
Publishing. Available: https://www.oecd-ilibrary.org/environment/test-no-438-isolated-chicken-eye-test-method-for-identifying-ocular-corrosives-and-severe-irritants_9789264076310-en.
Takahashi Y, Koike M, Honda H, Ito Y, Sakaguchi H, Suzuki H, Nishiyama
N. 2008. Development of the short time exposure (STE) test: an in vitro
eye irritation test using SIRC cells. Toxicol In Vitro 22:760-770.
Dated: July 5, 2012.
John R. Bucher,
Associate Director, National Toxicology Program.
[FR Doc. 2012-17118 Filed 7-12-12; 8:45 am]
BILLING CODE 4140-01-P